X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (322) 322
Book Review (68) 68
Publication (41) 41
Newsletter (7) 7
Magazine Article (6) 6
Book Chapter (4) 4
Newspaper Article (3) 3
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
dutasteride (300) 300
index medicus (258) 258
male (235) 235
humans (231) 231
finasteride (128) 128
middle aged (93) 93
prostate cancer (89) 89
urology & nephrology (82) 82
benign prostatic hyperplasia (81) 81
aged (76) 76
animals (74) 74
dihydrotestosterone (73) 73
testosterone (73) 73
men (69) 69
azasteroids - therapeutic use (66) 66
prostate (66) 66
5-alpha reductase inhibitors - therapeutic use (64) 64
prostatic hyperplasia - drug therapy (64) 64
endocrinology & metabolism (62) 62
cancer (60) 60
azasteroids - pharmacology (51) 51
hyperplasia (50) 50
androgens (46) 46
5-alpha reductase inhibitors (44) 44
prostatic neoplasms - drug therapy (44) 44
finasteride - therapeutic use (43) 43
adult (42) 42
pharmacology & pharmacy (42) 42
prostatic neoplasms - pathology (41) 41
5-alpha reductase inhibitors - pharmacology (40) 40
treatment outcome (40) 40
3-oxo-5-alpha-steroid 4-dehydrogenase - metabolism (39) 39
dihydrotestosterone - metabolism (38) 38
research (37) 37
risk factors (35) 35
prostate - drug effects (33) 33
finasteride - pharmacology (32) 32
oncology (32) 32
prostate - metabolism (32) 32
risk (32) 32
aged, 80 and over (31) 31
testosterone - metabolism (31) 31
abridged index medicus (30) 30
care and treatment (29) 29
expression (29) 29
5-alpha reductase inhibitors - adverse effects (28) 28
cell line, tumor (28) 28
prostatic neoplasms - prevention & control (28) 28
article (27) 27
dihydrotestosterone - blood (27) 27
dutasteride - therapeutic use (27) 27
prostate - pathology (27) 27
steroid 5-alpha-reductase (27) 27
testosterone - blood (27) 27
dual 5-alpha-reductase inhibitor (26) 26
efficacy (26) 26
enzyme inhibitors - therapeutic use (26) 26
analysis (25) 25
enzyme inhibitors - pharmacology (25) 25
receptors, androgen - metabolism (25) 25
5-alpha reductase inhibitors - administration & dosage (24) 24
combination therapy (24) 24
double-blind method (24) 24
prostatic neoplasms - metabolism (24) 24
therapy (24) 24
urology (24) 24
prevention (23) 23
safety (23) 23
rats (22) 22
azasteroids - administration & dosage (21) 21
dose-response relationship, drug (21) 21
androgenetic alopecia (20) 20
androgens - metabolism (20) 20
apoptosis (20) 20
health aspects (20) 20
hypertrophy (20) 20
metabolism (20) 20
prostatic hyperplasia - pathology (20) 20
urinary-tract symptoms (20) 20
administration, oral (19) 19
androgen receptor (19) 19
disease progression (19) 19
female (19) 19
finasteride - adverse effects (19) 19
progression (19) 19
prospective studies (19) 19
prostatic neoplasms - enzymology (19) 19
mice (18) 18
androgen antagonists - therapeutic use (17) 17
dutasteride - pharmacology (17) 17
prostatic neoplasms - genetics (17) 17
reductase (17) 17
3-oxo-5-alpha-steroid 4-dehydrogenase - genetics (16) 16
alopecia - drug therapy (16) 16
cell proliferation - drug effects (16) 16
enzymes (16) 16
prostate-specific antigen - blood (16) 16
prostatic hyperplasia - metabolism (16) 16
young adult (16) 16
5-alpha-reductase inhibitor (15) 15
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature, ISSN 0028-0836, 05/2016, Volume 533, Issue 7604, pp. 547 - 551
Abiraterone blocks androgen synthesis and prolongs survival in patients with castration-resistant prostate cancer, which is otherwise driven by intratumoral... 
ACTIVATION | CYP17A1 INHIBITION | RAT | MULTIDISCIPLINARY SCIENCES | ANDROGEN-RECEPTOR | BIOLOGY | MEN | RESISTANCE | STEROID 5-ALPHA-REDUCTASE | DIHYDROTESTOSTERONE | DEHYDROGENASE | Prostatic Neoplasms - metabolism | Dutasteride - therapeutic use | Humans | Receptors, Androgen - metabolism | Androgens - biosynthesis | Male | Androstenes - pharmacology | Abiraterone Acetate - administration & dosage | 3-Oxo-5-alpha-Steroid 4-Dehydrogenase - metabolism | Oxidation-Reduction - drug effects | Prostatic Neoplasms - blood | Androstenes - blood | Prostatic Neoplasms - drug therapy | Administration, Oral | Prostatic Neoplasms, Castration-Resistant - blood | Androgen Antagonists - pharmacology | 5-alpha Reductase Inhibitors - therapeutic use | Abiraterone Acetate - therapeutic use | Dutasteride - pharmacology | Prostatic Neoplasms, Castration-Resistant - drug therapy | Androstenes - administration & dosage | Prostatic Neoplasms, Castration-Resistant - metabolism | Disease Progression | Xenograft Model Antitumor Assays | Animals | Abiraterone Acetate - blood | Abiraterone Acetate - metabolism | 5-alpha Reductase Inhibitors - pharmacology | Androgen Antagonists - therapeutic use | Androstenes - metabolism | Cell Line, Tumor | Mice | Physiological aspects | Prostate cancer | Care and treatment | Enzymes | Androgens | Metabolites | Oxidation | Metabolism | Gene expression | Steroids | Index Medicus
Journal Article
Journal of Steroid Biochemistry and Molecular Biology, ISSN 0960-0760, 11/2017, Volume 174, pp. 242 - 256
Dutasteride is a 5alpha-reductase inhibitor in clinical use to treat endocrine conditions. The present study investigated the neuroprotective mechanisms of... 
Neuroprotection | Basal ganglia | MPTP | Astrocyte | Parkinson’s disease | Parkinson's disease | 17-BETA-HYDROXYSTEROID-DEHYDROGENASE TYPE 10 | NEURODEGENERATIVE DISORDERS | TESTOSTERONE | BIOCHEMISTRY & MOLECULAR BIOLOGY | FINASTERIDE | DOPAMINE TRANSPORTER | VESICULAR MONOAMINE TRANSPORTERS | NEUROACTIVE STEROID-LEVELS | FEMALE RATS | DISEASE | ENDOCRINOLOGY & METABOLISM | GENDER-DIFFERENCES | Neuroprotective Agents - therapeutic use | Dopamine Plasma Membrane Transport Proteins - metabolism | Vesicular Monoamine Transport Proteins - metabolism | Dutasteride - therapeutic use | MPTP Poisoning - physiopathology | Male | Glial Fibrillary Acidic Protein - metabolism | Receptors, Dopamine D2 - metabolism | Receptors, Dopamine D1 - metabolism | Brain - metabolism | Neuroprotective Agents - pharmacology | Androgens - blood | Behavior, Animal - drug effects | Dopamine - metabolism | Testosterone Congeners - blood | Mice, Inbred C57BL | 5-alpha Reductase Inhibitors - therapeutic use | Dutasteride - pharmacology | Psychomotor Performance - drug effects | MPTP Poisoning - drug therapy | Dopamine Plasma Membrane Transport Proteins - genetics | Brain - drug effects | Animals | MPTP Poisoning - metabolism | Testosterone Congeners - metabolism | 5-alpha Reductase Inhibitors - pharmacology | Androgens - metabolism | Index Medicus
Journal Article
Reproduction, ISSN 1470-1626, 2018, Volume 155, Issue 3, pp. 251 - 258
In the latter half of gestation in the mare, progesterone concentrations decline to near undetectable levels while other 5 alpha-reduced pregnanes are... 
REPRODUCTIVE BIOLOGY | PROGESTERONE | BLOOD-PLASMA | COWS | DEVELOPMENTAL BIOLOGY | FETAL | PARTURITION | EQUINE | RETAINED PLACENTA | MASS-SPECTROMETRY | 5-ALPHA-DIHYDROPROGESTERONE | DUTASTERIDE | Index Medicus
Journal Article
Journal Article
Journal Article
Journal Article
Neuropharmacology, ISSN 0028-3908, 10/2015, Volume 97, pp. 86 - 94
Journal Article
American Journal of Pathology, The, ISSN 0002-9440, 2015, Volume 185, Issue 3, pp. 614 - 616
This commentary highlights the article by Ge et al, which proposes the use of methylation and expression of SRD5A2 as a gene signature to tailor therapies for... 
Pathology | INFLAMMATION | TISSUE | BPH | PATHOLOGY | HYPERPLASIA | EXPRESSION | DUTASTERIDE | DNA (Cytosine-5-)-Methyltransferases - metabolism | Animals | Humans | 3-Oxo-5-alpha-Steroid 4-Dehydrogenase - metabolism | Male | Membrane Proteins - metabolism | Prostate - metabolism | Aging - metabolism | Prostatic Hyperplasia - metabolism | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2014, Volume 32, Issue 3, pp. 229 - 237
Purpose Ligand-mediated activation of the androgen receptor (AR) is critical for prostate cancer (PCa) survival and proliferation. The failure to completely... 
THERAPY | NEOADJUVANT CHEMOTHERAPY | ONCOLOGY | TESTOSTERONE | ADENOCARCINOMA | GROWTH | RECEPTOR | RADICAL PROSTATECTOMY | CASTRATION | SPLICE VARIANTS | DIHYDROTESTOSTERONE | Prostatic Neoplasms - metabolism | Steroid 17-alpha-Hydroxylase - antagonists & inhibitors | Androgen Receptor Antagonists - therapeutic use | Ketoconazole - administration & dosage | Humans | Middle Aged | Receptors, Androgen - metabolism | Male | Prostate - metabolism | Nitriles - administration & dosage | Antineoplastic Agents, Hormonal - therapeutic use | Dihydrotestosterone - blood | Aged, 80 and over | Androsterone - blood | Biomarkers, Tumor - metabolism | Prostatic Neoplasms - blood | Chemotherapy, Adjuvant | Testosterone - blood | Molecular Targeted Therapy - methods | Prostatic Neoplasms - drug therapy | Dihydrotestosterone - metabolism | Goserelin - administration & dosage | Prostatic Neoplasms - pathology | Tosyl Compounds - administration & dosage | Treatment Outcome | Prostate-Specific Antigen - blood | Pilot Projects | Azasteroids - administration & dosage | Receptors, Androgen - genetics | Anilides - administration & dosage | Signal Transduction - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoadjuvant Therapy - methods | 5-alpha Reductase Inhibitors - administration & dosage | Androgen Antagonists - therapeutic use | Dutasteride | Aged | Neoplasm Staging | Index Medicus | ORIGINAL REPORTS | To16
Journal Article
PLoS ONE, ISSN 1932-6203, 02/2013, Volume 8, Issue 2, pp. e55905 - e55905